naringenin has been researched along with 2019 Novel Coronavirus Disease in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 8 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Brahmasundari, S; Madeswaran, A; Midhuna, PG | 1 |
| AmeliMojarad, M | 1 |
| Huang, XF; Jiao, X; Song, WX; Wang, K; Wu, P; Wu, WY; Xiao, PQ; Zhan, SF | 1 |
| Hosseinzadeh-Attar, MJ; Naeini, F; Ostadrahimi, A; Tutunchi, H | 1 |
| Antonelli, G; Carpaneto, A; Clementi, M; Clementi, N; Criscuolo, E; D'Amore, A; Filippini, A; Frasca, F; Mancini, N; Palombi, F; Pierangeli, A; Scagnolari, C | 1 |
| Alberca, RW; Andrade, MMS; Beserra, DR; de Oliveira, EA; Pietrobon, AJ; Sato, MN; Teixeira, FME | 1 |
| Di Maria, E; Gennarelli, M; Martini, P | 1 |
| Carpaneto, A; Ceccarelli, M; D'Amore, A; Filippini, A; Gradogna, A; Minicozzi, V; Palombi, F | 1 |
3 review(s) available for naringenin and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
Interleukin-6 inhibitory effect of natural product naringenin compared to a synthesised monoclonal antibody against life-threatening COVID-19.
Topics: Anti-Inflammatory Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; COVID-19; Humans; Interleukin-6; SARS-CoV-2 | 2023 |
Naringenin, a flavanone with antiviral and anti-inflammatory effects: A promising treatment strategy against COVID-19.
Topics: Animals; Anti-Inflammatory Agents; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Flavanones; Humans; SARS-CoV-2 | 2020 |
The Discovery of Naringenin as Endolysosomal Two-Pore Channel Inhibitor and Its Emerging Role in SARS-CoV-2 Infection.
Topics: Antineoplastic Agents; Antiviral Agents; Arabidopsis; Calcium Channel Blockers; Calcium Channels; COVID-19; COVID-19 Drug Treatment; Drug Evaluation, Preclinical; Endosomes; Flavanones; Humans; Lysosomes; Neoplasms; Neovascularization, Pathologic; Pandemics; SARS-CoV-2; Vacuoles; Virus Internalization | 2021 |
5 other study(ies) available for naringenin and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
In silico molecular docking studies of certain commercially available flavonoids as effective antiviral agents against spike glycoprotein of SARS-CoV-2.
Topics: Antiviral Agents; Binding Sites; Catechin; COVID-19; Flavanones; Flavonoids; Humans; Molecular Docking Simulation; SARS-CoV-2; Spike Glycoprotein, Coronavirus | 2021 |
Network pharmacology and bioinformatics analysis identifies potential therapeutic targets of
Topics: Antiviral Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; COVID-19; Humans; Lung Neoplasms; Molecular Docking Simulation; Network Pharmacology; Phosphatidylinositol 3-Kinases | 2023 |
Naringenin is a powerful inhibitor of SARS-CoV-2 infection in vitro.
Topics: COVID-19; Flavanones; Humans; Pharmaceutical Preparations; SARS-CoV-2 | 2021 |
Perspective: The Potential Effects of Naringenin in COVID-19.
Topics: Animals; Anti-Inflammatory Agents; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; Cytokine Release Syndrome; Cytokines; Disease Models, Animal; Flavanones; Humans; Macrophages; Pandemics; Pneumonia, Viral; SARS-CoV-2; Virus Replication | 2020 |
Naringerin as candidate drug against SARS-CoV-2: The role for TPC2 genomic variants in COVID-19.
Topics: COVID-19; Flavanones; Genomics; Humans; Pharmaceutical Preparations; SARS-CoV-2 | 2021 |